Research Project on the Interaction Between Immune Function and Infectious Diseases in Older Adults and the Development of Prevention and Control Strategies
As population aging accelerates, infectious diseases have become a major factor affecting the health, quality of life, and survival outcomes of older adults. Immunosenescence, chronic low-grade inflammation (inflammaging), and dysbiosis of the respiratory and gut microbiota are considered important mechanisms underlying increased susceptibility to infection and a higher risk of severe disease in older adults. However, the interactions among these factors and their impact on infection-related outcomes remain incompletely understood.
Building upon a previously established pilot cohort of older adults, this study aims to further identify and validate key biological characteristics and risk factors associated with infectious diseases through large-scale population follow-up. A large prospective cohort of older adults will be established, while retrospective healthcare data collected since 2019 will also be integrated. Demographic information, comorbidities, medication history, infection-related clinical data, and biological specimens, including blood, urine, fecal, and respiratory samples, will be collected for long-term longitudinal follow-up. By integrating immunological assessments, immune repertoire analyses, microbiome profiling, and other multi-omics technologies, this study will systematically evaluate the effects of immunosenescence, respiratory and gut microbiome alterations, and environmental and climatic factors on the occurrence, severity, and prognosis of infectious diseases in older adults. The study aims to identify key biomarkers and microbial signatures associated with infection risk and to develop risk prediction and early warning models for infectious diseases in older adults, thereby providing scientific evidence for precision prevention, optimized clinical management, and public health decision-making in aging populations.
調査の概要
研究の種類
入学 (推定)
連絡先と場所
研究連絡先
- 名前：Jingwen Ai
- 電話番号：17317958269
- メール：jingwenai1990@126.com
参加基準
適格基準
就学可能な年齢
- 大人
- 高齢者
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- General Cohort Inclusion Criteria
- Adults aged 60 years or older who are in generally good health, defined as having no severe organ dysfunction that significantly affects daily living activities (e.g., decompensated heart, liver, or kidney failure), adequate nutritional status (without significant wasting or malnutrition), and the ability to communicate and comply with study procedures.
- Male or female.
- Able to understand the study and voluntarily provide written informed consent.
Infection Cohort Inclusion Criteria
- Adults aged 60 years or older, regardless of sex.
- Patients with an infectious disease diagnosed by a qualified clinician.
Exclusion Criteria:
General Cohort Exclusion Criteria
- Refusal to participate in this study.
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.
Infection Cohort Exclusion Criteria
- Final primary diagnosis is a non-infectious disease (e.g., connective tissue disease, malignancy, or other non-infectious conditions).
- Positive culture results determined by the treating clinician to represent colonization or contamination rather than true infection.
- Refusal to participate in this study.
- Critically ill patients or those unable to cooperate with specimen collection procedures.
- Any other condition that, in the opinion of the investigator, makes the participant unsuitable for enrollment.
研究計画
研究はどのように設計されていますか？
デザインの詳細
コホートと介入
グループ/コホート |
|---|
|
Older Adults Without Infection
Community-dwelling adults aged 60 years and older who do not develop any clinically diagnosed infectious disease during the follow-up period.
|
|
Older Adults With Infection
Community-dwelling adults aged 60 years and older who develop clinically diagnosed infectious diseases during follow-up.
|
この研究は何を測定していますか？
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Occurrence of infectious disease outcomes in older adults
時間枠：Baseline to 3 years
|
Occurrence of infectious disease outcomes in older adults, including all-cause mortality, infection-related mortality, first infectious disease event, and progression to severe infection.
|
Baseline to 3 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
High-Frequency Infection Status (≥6 Infections per Year)
時間枠：Baseline to 3 Years
|
Defined as an average of six or more infectious episodes per year during follow-up.
|
Baseline to 3 Years
|
|
Pathogen-Specific Infection Events
時間枠：Baseline to 3 Years
|
Infectious disease events caused by specific pathogens, used to evaluate pathogen distribution and temporal trends.
|
Baseline to 3 Years
|
|
Changes in Immune Function Biomarkers
時間枠：Baseline to 3 Years
|
Assessment of longitudinal changes in immune cell subsets and immune function status.
|
Baseline to 3 Years
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Changes in Metabolomic and Microbiome Profiles
時間枠：Baseline to 3 Years
|
Assessment of longitudinal changes in metabolomic profiles and gut and respiratory microbiome characteristics associated with infection risk and disease severity.
|
Baseline to 3 Years
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 20260306-001
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。